Table 2.
Treatment patterns for patients with advanced and recurrent EC.
| Patients Who Received: | Overall | Advanced EC | Recurrent EC |
|---|---|---|---|
| (N = 1053) | (N = 620; 58.9%) | (N = 433; 41.1%) | |
| No systemic therapy | N = 340 (32.3%) | N = 154 (24.8%) | N = 186 (43.0%) |
| 1L systemic therapy, n (%) | N = 713 (67.7%) | N = 466 (75.2%) | N = 247 (57.0%) |
| Platinum combination | 506 (71.0) | 410 (88.0) | 96 (38.9) |
| Platinum monotherapy | 54 (7.6) | 38 (8.2) | 16 (6.5) |
| Non-platinum combination |
41 (5.8) | <10 (<2.1) | 66 (26.7) |
| Non-platinum monotherapy |
28 (3.9) | ||
| Progestational agent/hormone therapy | 84 (11.8) | 15 (3.2) | 69 (27.9) |
| 2L systemic therapy, n (%) | N = 257 (24.4%) | N = 169 (27.3%) | N = 88 (20.32%) |
| Platinum combination | 97 (37.7) | 79 (46.7) | 18 (20.5) |
| Platinum monotherapy | 20 (7.8) | >10 (>5.9) | <10 (<11.4) |
| Non-platinum combination | 18 (7.0) | <10 (<5.9) | >8 (>9.1) |
| Non-platinum monotherapy | 85 (33.1) | 45 (26.6) | 40 (45.5) |
| Progestational agent/hormone therapy | 37 (14.4) | 25 (14.8) | 12 (13.6) |
| 2L systemic therapy following 1L PBCT, n (%) | N = 187 (17.8%) | N = 144 (23.2%) | N = 43 (9.9) |
| Platinum combination | 96 (51.3) | 79 (54.9) | 17 (39.5) |
| Platinum monotherapy | 19 (10.2) | >9 (6.3) | <10 (<23.0) |
| Non-platinum combination | <10 (<5.3) | <10 (<6.9) | <10 (<23.0) |
| Non-platinum monotherapy | 65 (34.8) | 44 (30.6) | 21 (48.8) |
| 3L systemic therapy, n (%) | N = 90 (8.5%) | N = 39–57 (<9.2%) | N = 33–41 (<9.5%) |
| Non-platinum monotherapy | 40 (44.4) | 22 | 18 |
| Platinum combination | 22 (24.4) | >13 | <10 |
| Other chemotherapy | <10 (<11.1) | <10 | <10 |
| Progestational agent/hormone therapy | 19 (21.1) | >10 | <10 |
Due to privacy regulations, cell counts <10 cannot be disclosed. Individual percentage values are rounded and may not total 100%. 1L, first line; 2L, second line; 3L, third line; EC, endometrial cancer; PBCT, platinum-based chemotherapy.